Gene Salkind, 68, Director. Gene Salkind, M.D. has been a practicing neurosurgeon for more than 35 years outside of Philadelphia, PA. He graduated from the University of Pennsylvania in 1974 with a B.A., Cum Laude, and received his medical degree from the Lewis Katz School of Medicine in 1979. He returned to the University of Pennsylvania for his neurosurgical residency and in 1985 was selected as the Chief Resident in Neurosurgery at the Hospital of the University of Pennsylvania. Since that time, he has been in a university affiliated practice of general neurological surgery. He is currently the Chief of Neurosurgery at Holy Redeemer Hospital and has also been the Chief of Neurosurgery at Albert Einstein Medical Center and Jeanes Hospital in Philadelphia. He has authored numerous peer reviewed journal articles and has given lectures throughout the country on various neurosurgical topics. He has held professorships at the University of Pennsylvania, the Allegheny Health Education and Research Foundation, and currently at the Lewis Katz School of Medicine.
Dr. Salkind is a prominent investor in the pharmaceutical arena. Past investments include Intuitive Surgical, Pharmacyclics, which grew from less than $1 per share to subsequently being acquired by Abbvie for $250 per share, and Centocor, one of the nation’s largest biotechnology companies, which was acquired by Johnson & Johnson for $4.9 billion in stock. Dr. Salkind currently sits on the boards of Cure Pharmaceuticals, a leader in the biotechnology field through its continual pursuit of redefining traditional drug delivery, and Mobiquity Technologies, Inc., a digital engagement provider. Mobiquity owns and operates a national location based mobile advertising network. The company’s suite of technologies allows clients to execute personalized and relevant experiences, driving brand awareness and incremental revenue. He was previously a board member of Derm Tech International, a global leader in non-invasive dermatological molecular diagnostics.
Dr. Salkind in 2019 joined the Strategic Advisory Board of Bio Symetrics, a company that has built data services tools for automated pre-processing, integrated analytics, and predictive modeling to make machine learning accessible to scientists and providers. Their technology serves health and hospital systems, biopharma, drug discovery and precision medicine. Dr. Salkind is and has been an employee and shareholder of Leonard A. Bruno MD/ Gene Salkind MD for the past five years. Dr. Salkind, a member of our audit committee, currently owns greater than ten percent (10%) of the outstanding voting securities of the Company.
What is Gene Salkind's net worth?
The estimated net worth of Gene Salkind is at least $623.44 thousand as of November 20th, 2025. Salkind owns 218,750 shares of Upexi stock worth more than $623,438 as of December 5th. This net worth approximation does not reflect any other assets that Salkind may own. Learn More about Gene Salkind's net worth.
How do I contact Gene Salkind?
Has Gene Salkind been buying or selling shares of Upexi?
Within the last three months, Gene Salkind has bought $392,500.00 of Upexi stock. Most recently, on Thursday, November 20th, Gene Salkind bought 50,000 shares of Upexi stock. The stock was acquired at an average cost of $2.55 per share, with a total value of $127,500.00. Following the completion of the transaction, the director now directly owns 218,750 shares of the company's stock, valued at $557,812.50. Learn More on Gene Salkind's trading history.
Who are Upexi's active insiders?
Are insiders buying or selling shares of Upexi?
In the last twelve months, Upexi insiders bought shares 10 times. They purchased a total of 1,291,170 shares worth more than $3,540,262.36. The most recent insider tranaction occured on November, 20th when Director Gene Salkind bought 50,000 shares worth more than $127,500.00. Insiders at Upexi own 4.4% of the company.
Learn More about insider trades at Upexi. Information on this page was last updated on 11/20/2025.
